Palisade Bio (NASDAQ: PALI) boosts PALI-2108 to Phase 2 with $125M cash runway
Rhea-AI Filing Summary
Palisade Bio reported second quarter 2026 results and progress on its lead IBD candidate PALI-2108. The company highlighted favorable Phase 1 safety, exposure and pharmacodynamic data, with all 5 ulcerative colitis patients showing clinical response and 2 achieving remission, and a roughly 47.5% mean SES-CD reduction in fibrostenotic Crohn’s disease patients.
PALI-2108 is advancing into Phase 2 trials: the ASCENTRA-UC study is expected to start in the second half of 2026 with primary efficacy results in the second half of 2027, and an IND for the ASCENTRA-CD Phase 2 trial is planned for the second half of 2026, with primary readout in early 2028. For the quarter ended June 30, 2026, Palisade reported $0.5 million in license revenue, research and development expenses of $7.4 million, general and administrative expenses of $4.8 million and a net loss of $10.6 million or $0.05 per share. Cash and cash equivalents were $125.2 million as of June 30, 2026, which the company believes will fund operations through the planned Phase 2 efficacy readouts.
Positive
- Cash and cash equivalents of $125.2 million as of June 30, 2026, with the company stating this is sufficient to fund operations through primary efficacy readouts for both Phase 2 ASCENTRA-UC (2H 2027) and ASCENTRA-CD (early 2028).
- Encouraging Phase 1 data for PALI-2108, including 5/5 clinical responses and 2/5 remissions in ulcerative colitis patients, and approximately 47.5% mean SES-CD reduction in fibrostenotic Crohn’s disease patients.
- Regulatory momentum with FDA clearance of the IND for the Phase 2 ASCENTRA-UC trial and plans to submit an IND for the Phase 2 ASCENTRA-CD trial in the second half of 2026.
Negative
- Quarterly net loss increased to $10.6 million (three months ended June 30, 2026) from $2.8 million a year earlier, reflecting significantly higher operating expenses.
- Research and development expenses rose to $7.4 million from $1.7 million year over year for the quarter, driven by expanded PALI-2108 clinical, CMC and translational activities.
- General and administrative expenses increased to $4.8 million from $1.2 million for the quarter, mainly due to higher employee-related costs and professional fees.
Filing Explained
Common shares issued and outstanding reached 173.6 million; the 450 million authorization is capacity, not completed issuance.
This Form 8-K reports Palisade Bio’s financial results and other material company updates as of
Common stock issued and outstanding rose from 159,444,017 shares at
Because issuing additional shares increases the total share count, holders whose share counts did not increase correspondingly have a lower percentage ownership, absent offsetting changes. The company also reported
8-K Event Classification
Key Figures
Key Terms
PDE4 inhibitor prodrug medical
investigational new drug (IND) regulatory
fibrostenotic Crohn’s disease medical
contingent consideration obligation financial
accumulated deficit financial
Earnings Snapshot
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Palisade Bio (PALI) key financial results for Q2 2026?
How strong is Palisade Bio (PALI) cash position as of June 30, 2026?
What clinical progress did Palisade Bio (PALI) report for PALI-2108?
When will Palisade Bio (PALI) start its Phase 2 ASCENTRA-UC trial?
What are Palisade Bio (PALI) plans for PALI-2108 in Crohn’s disease?
How did Palisade Bio (PALI) operating expenses change year over year in Q2 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 10, 2026, Palisade Bio, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information in Item 2.02 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
|
Description |
99.1 |
|
Palisade Bio, Inc. Press Release issued on August 10, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
PALISADE BIO, INC. |
|
|
|
|
Date: |
August 10, 2026 |
By: |
/s/ J.D. Finley |
|
|
|
J.D. Finley |
EXHIBIT 99.1
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD)
Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027
IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026
Strong balance sheet expected to support execution through key Phase 2 clinical readouts
Denver, CO, August 10, 2026 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. During the quarter, the Company completed key regulatory and operational activities supporting the planned commencement of the Phase 2 ASCENTRA-UC trial of PALI-2108 in the second half of 2026.
Palisade Bio is advancing PALI-2108 into Phase 2 development for ulcerative colitis (UC) and Crohn’s disease (CD), supported by encouraging results from its completed Phase 1 clinical trial.
Key Takeaways from the Phase 1 Clinical Trial
EXHIBIT 99.1
Together, these findings provide a strong foundation for the planned commencement of the Phase 2 ASCENTRA-UC trial in the second half of 2026. The Company also intends to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Phase 2 ASCENTRA-CD trial of PALI-2108 in the second half of 2026.
“The second quarter marked a decisive transition for Palisade Bio as we completed the regulatory and operational work required to advance PALI-2108 into Phase 2 development,” said JD Finley, Chief Executive Officer of Palisade Bio. “With FDA clearance of our IND, encouraging Phase 1 results and a strong financial position, we expect to commence the Phase 2 ASCENTRA-UC trial in the second half of 2026. PALI-2108 was engineered for targeted activation within the gastrointestinal tract, with the goal of delivering sustained PDE4 inhibition while improving tolerability and convenience. We believe the ASCENTRA-UC Phase 2 trial represents a significant opportunity to demonstrate that differentiated profile in a larger patient population and establish PALI-2108 as a potentially best-in-class, once-daily oral therapy for IBD.”
Recent Highlights
Scientific Presentations
Advancing PALI-2108 Into Phase 2 Development
Phase 2 ASCENTRA-UC
EXHIBIT 99.1
Phase 2 ASCENTRA-CD
Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio, added, “Crohn’s disease is a core component of the PALI-2108 clinical development program and is advancing in parallel with ASCENTRA-UC. We believe that PALI-2108’s targeted activation and localized delivery in both the ileum and colon are particularly relevant to Crohn’s disease, which can affect multiple regions of the gastrointestinal tract. We are finalizing the design of the Phase 2 ASCENTRA-CD trial and expect to submit an IND in the second half of 2026. With active programs in both Crohn’s disease and ulcerative colitis, PALI-2108 is positioned to address the two largest indications within IBD.”
Summary of Financial Results
Research and development expenses were $7.4 million for the three months ended June 30, 2026, compared to $1.7 million for the three months ended June 30, 2025. The increase was primarily attributable to higher research and development employee-related expenses, including increased non-cash stock-based compensation expense, and higher PALI-2108 program expenses driven by increased clinical operation expenses, increased chemistry, manufacturing and controls (CMC) activities and expanded preclinical and translational science efforts supporting advancement of PALI-2108 into Phase 2 development.
General and administrative expenses were $4.8 million for the three months ended June 30, 2026, compared to $1.2 million for the three months ended June 30, 2025. The increase was primarily attributable to higher employee-related expenses, including increased non-cash stock-based compensation expense, as well as higher professional fees supporting the Company's continued growth and clinical advancement.
The Company recognized license revenue of $0.5 million for the three months ended June 30, 2026 related to the achievement of a milestone pursuant the co-development and distribution agreement with Newsoara, a joint venture established by Biolead Medical Technology Limited. No license revenue was recognized for the three months ended June 30, 2025.
Net loss was $10.6 million, or a net loss of $0.05 per share, for the three months ended June 30, 2026, compared to a net loss of $2.8 million, or a net loss of $0.58 per share, for the three months ended June 30, 2025.
As of June 30, 2026, the Company had $125.2 million in cash and cash equivalents and believes its existing cash resources are sufficient to fund operations through major clinical development milestones, including the anticipated primary efficacy readout from the Phase 2 ASCENTRA-UC
EXHIBIT 99.1
trial expected in the second half of 2027 and the planned primary efficacy readout from the Phase 2 ASCENTRA-CD trial expected in early 2028.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company developing prodrugs for patients living with inflammatory and fibrotic diseases.
The Company’s lead clinical product candidate, PALI-2108, is being advanced into Phase 2 clinical trials as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Despite the availability of multiple biologic and small-molecule therapies, many patients with UC and CD do not achieve durable remission, lose response over time, or discontinue treatment because of safety or tolerability limitations. The Company believes PALI-2108 has the potential to address these limitations through once-daily oral dosing, targeted lower-intestinal bioactivation and broad PDE4-mediated anti-inflammatory activity.
Palisade Bio is now advancing into Phase 2 development for UC and CD. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: implied or express statements regarding the pharmacological properties, safety, tolerability, clinical response and efficacy, and therapeutic potential of PALI-2108, dosing levels and timing of key PALI-2108 development milestones such as regulatory submissions and approvals, trial enrollments and commencements and efficacy readouts, and the Company's expected cash runway. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing or durability of effect, observed from preclinical or clinical trials with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the
EXHIBIT 99.1
Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
EXHIBIT 99.1
Palisade Bio, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share amounts)
|
|
June 30, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
125,172 |
|
|
$ |
133,385 |
|
Accounts receivable |
|
|
500 |
|
|
|
— |
|
Prepaid expenses and other current assets |
|
|
1,588 |
|
|
|
836 |
|
Total current assets |
|
|
127,260 |
|
|
|
134,221 |
|
Restricted cash |
|
|
55 |
|
|
|
55 |
|
Other noncurrent assets |
|
|
— |
|
|
|
68 |
|
Total assets |
|
$ |
127,315 |
|
|
$ |
134,344 |
|
|
|
|
|
|
|
|
||
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
1,835 |
|
|
$ |
767 |
|
Accrued liabilities |
|
|
3,136 |
|
|
|
2,187 |
|
Accrued compensation and benefits |
|
|
275 |
|
|
|
1,298 |
|
Share liability |
|
|
— |
|
|
|
313 |
|
Insurance financing debt |
|
|
— |
|
|
|
71 |
|
Total current liabilities |
|
|
5,246 |
|
|
|
4,636 |
|
Derivative liability |
|
|
62 |
|
|
|
62 |
|
Contingent consideration obligation |
|
|
259 |
|
|
|
266 |
|
Total liabilities |
|
|
5,567 |
|
|
|
4,964 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders' equity: |
|
|
|
|
|
|
||
Series A Convertible Preferred Stock, $0.01 par value, |
|
|
2 |
|
|
|
2 |
|
Common stock, $0.01 par value; 450,000,000 and 300,000,000 shares |
|
|
1,735 |
|
|
|
1,594 |
|
Additional paid-in capital |
|
|
292,910 |
|
|
|
280,509 |
|
Accumulated deficit |
|
|
(172,899 |
) |
|
|
(152,725 |
) |
Total stockholders' equity |
|
|
121,748 |
|
|
|
129,380 |
|
Total liabilities and stockholders' equity |
|
$ |
127,315 |
|
|
$ |
134,344 |
|
|
|
|
|
|
|
|
||
EXHIBIT 99.1
Palisade Bio, Inc.
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share amounts)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
License revenue |
|
$ |
500 |
|
|
$ |
— |
|
|
$ |
500 |
|
|
$ |
— |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
7,400 |
|
|
|
1,675 |
|
|
|
13,797 |
|
|
|
2,625 |
|
General and administrative |
|
|
4,798 |
|
|
|
1,168 |
|
|
|
9,149 |
|
|
|
2,528 |
|
Total operating expenses |
|
|
12,198 |
|
|
|
2,843 |
|
|
|
22,946 |
|
|
|
5,153 |
|
Loss from operations |
|
|
(11,698 |
) |
|
|
(2,843 |
) |
|
|
(22,446 |
) |
|
|
(5,153 |
) |
Other (expense) income: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense |
|
|
— |
|
|
|
(2 |
) |
|
|
(1 |
) |
|
|
(3 |
) |
Other income, net |
|
|
1,124 |
|
|
|
61 |
|
|
|
2,273 |
|
|
|
142 |
|
Total other income, net |
|
|
1,124 |
|
|
|
59 |
|
|
|
2,272 |
|
|
|
139 |
|
Net loss |
|
$ |
(10,574 |
) |
|
$ |
(2,784 |
) |
|
$ |
(20,174 |
) |
|
$ |
(5,014 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic and diluted weighted average shares used in computing basic and diluted net loss per common share |
|
|
211,381,969 |
|
|
|
4,797,196 |
|
|
|
210,528,231 |
|
|
|
4,796,434 |
|
Basic and diluted net loss per common share |
|
$ |
(0.05 |
) |
|
$ |
(0.58 |
) |
|
$ |
(0.10 |
) |
|
$ |
(1.05 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
EXHIBIT 99.1
Palisade Bio, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
|
|
Six Months Ended June 30, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
|
|
|
|
|||||
Net loss |
|
$ |
(20,174 |
) |
|
$ |
(5,014 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
||
Depreciation |
|
|
— |
|
|
|
2 |
|
Non-cash operating lease expense |
|
|
— |
|
|
|
62 |
|
Recurring fair value measurements of liabilities |
|
|
(7 |
) |
|
|
(9 |
) |
Write-off of deferred equity issuance costs |
|
|
— |
|
|
|
75 |
|
Stock-based compensation and related charges |
|
|
9,082 |
|
|
|
138 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
(500 |
) |
|
|
— |
|
Prepaid and other current assets and other noncurrent assets |
|
|
(915 |
) |
|
|
(18 |
) |
Accounts payable and accrued liabilities |
|
|
2,044 |
|
|
|
1,210 |
|
Accrued compensation and benefits |
|
|
(1,023 |
) |
|
|
(530 |
) |
Operating lease liabilities |
|
|
— |
|
|
|
(66 |
) |
Net cash used in operating activities |
|
|
(11,493 |
) |
|
|
(4,150 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
||
Payments on insurance financing debt |
|
|
(71 |
) |
|
|
(80 |
) |
Proceeds from issuance of common stock |
|
|
3,250 |
|
|
|
— |
|
Proceeds from the exercise of warrants |
|
|
155 |
|
|
|
1 |
|
Payment of equity issuance costs |
|
|
(74 |
) |
|
|
(178 |
) |
Proceeds from issuance of common stock under Employee Stock Purchase Plan |
|
|
20 |
|
|
|
3 |
|
Net cash provided by (used in) financing activities |
|
|
3,280 |
|
|
|
(254 |
) |
Net decrease in cash, cash equivalents and restricted cash |
|
|
(8,213 |
) |
|
|
(4,404 |
) |
Cash, cash equivalents and restricted cash, beginning of year |
|
|
133,440 |
|
|
|
9,847 |
|
Cash, cash equivalents and restricted cash, end of period |
|
$ |
125,227 |
|
|
$ |
5,443 |
|
Reconciliation of cash, cash equivalents and restricted cash to the balance sheets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
125,172 |
|
|
$ |
5,417 |
|
Restricted cash |
|
|
55 |
|
|
|
26 |
|
Total cash, cash equivalents and restricted cash |
|
$ |
125,227 |
|
|
$ |
5,443 |
|
|
|
|
|
|
|
|
||